Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Abbott Laboratories: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Abbott Laboratories
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: Abbott Laboratories
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The firm trades with high earnings multiples: 31.66 times its 2026 earnings per share.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Rating Financials

Abbott Laboratories SectorBulgaria

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Abbott Laboratories SectorBulgaria

Global Valuation

-

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

-

P/E

PBR

-

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Abbott Laboratories SectorBulgaria

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Abbott Laboratories SectorBulgaria

Visibility

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Abbott Laboratories SectorBulgaria

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
191B
BBB
191B
BBB
116B
BBB
61.75B
AA
51.24B
A
51.51B
AAA
34.36B
BBB
30.73B
A
24.01B
AA
23.23B
AA
Average 77.48B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ABT Stock
  4. ABL Stock
  5. Ratings Abbott Laboratories